Medgenics, Inc. (NYSEMKT:MDGN) on 25 November announced the pricing of 5,125,000 shares of its common stock in a previously announced underwritten public offering at a price to the public of $4.10 per share. In connection with the offering, Medgenics has also granted the underwriters a 30-day option to purchase up to an additional 768,750 shares of its common stock. Medgenics, Inc. (NYSEMKT:MDGN) in last trading activity increased 8.50% to close at $4.47. Company weekly performance is 7.97% while its quarterly performance stands at -24.75%. Medgenics, Inc. (NYSEMKT:MDGN) is -50.33% away from its 52 week high.
David A.B. Brown, CEO and Chairman of the Board of Layne Christensen Company (NASDAQ:LAYN) announced the appointment of Michael J. Caliel as President and Chief Executive Officer, and Member of the Board of Directors, effective January 2, 2015. On last trading day Layne Christensen Company (NASDAQ:LAYN) increased 10.99% to close at $7.98. Its volatility for the week is 8.71% while volatility for the month is 6.66%. LAYN’s sales growth for past 5 years was -3.10% and its EPS growth for past 5 years was -47.60%. Layne Christensen Company (NASDAQ:LAYN) monthly performance is 3.91%.
Raymond James cut shares of Whiting USA Trust II (NYSE:WHZ) from a market perform rating to an underperform rating in a research note issued to investors on Monday, TheFlyOnTheWall.com reports. On last trading day Whiting USA Trust II (NYSE:WHZ) increased 7.02% to close at $6.86. Its volatility for the week is 11.74% while volatility for the month is 6.17%. Whiting USA Trust II (NYSE:WHZ) monthly performance is -39.35%.
Sandridge Mississippian Trust I (NYSE:SDT) posted its quarterly earnings results on Tuesday, November 18th. The company reported $0.36 earnings per share for the quarter, meeting the analysts’ consensus estimate of $0.36. Analysts expect that Sandridge Mississippian Trust I will post $1.69 EPS for the current fiscal year. SandRidge Mississippian Trust I (NYSE:SDT) has 2.52% insider ownership while its institutional ownership stands at 4.20%. In last trading activity company’s stock closed at $3.39.
Dicerna Pharmaceuticals (NASDAQ:DRNA) Insider James E. Flynn sold 321,965 shares of Dicerna Pharmaceuticals stock on the open market in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $11.36, for a total value of $3,657,522.40. On Wednesday shares of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) closed at $11.79.